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Abstract
Background: Colorectal cancer (CRC) screening is key to CRC prevention and mortality reduction, but patient
compliance with CRC screening is low. We previously reported a blood-based test for CRC that utilizes a seven-
gene panel of biomarkers. The test is currently utilized clinically in North America for CRC risk stratification in the
average-risk North American population in order to improve screening compliance and to enhance clinical decision
making.
Methods: In this study, conducted in Malaysia, we evaluated the seven-gene biomarker panel validated in a North
American population using blood samples collected from local patients. The panel employs quantitative RT-PCR
(qRT-PCR) to analyze gene expression of the seven biomarkers (ANXA3, CLEC4D, TNFAIP6, LMNB1, PRRG4, VNN1
and IL2RB) that are differentially expressed in CRC patients as compared with controls. Blood samples from 210
patients (99 CRC and 111 controls) were collected, and total blood RNA was isolated and subjected to quantitative
RT-PCR and data analysis.
Results: The logistic regression analysis of seven-gene panel has an area under the curve (AUC) of 0.76 (95%
confidence interval: 0.70 to 0.82), 77% specificity, 61% sensitivity and 70% accuracy, comparable to the data
obtained from the North American investigation of the same biomarker panel.
Conclusions: Our results independently confirm the results of the study conducted in North America and
demonstrate the ability of the seven biomarker panel to discriminate CRC from controls in blood samples drawn
from a Malaysian population.
Background
Colorectal cancer (CRC) is the second most common
cause of cancer mortality among men and women
worldwide, with an incidence of approximately 1 million
cases per year and more than 500,000 deaths [1].
Although long considered a “western disease”,C R Ci n
Asia has been increasing to North American and Eur-
opean levels. In Malaysia, CRC is the second most com-
mon cancer in women and has recently overtaken lung
cancer to become the most common cancer in men [2].
Population screening to reduce mortality from CRC has
been long and vigorously advocated. However screening
uptake remains less than optimal, with screening rates in
North America lower than 25% to 50% [3-5]. Low compli-
ance has been explained in part on the uncomfortable and
inconvenient nature of current CRC screening tests,
which, depending on the test, may require fecal samples,
years of commitment, bowel preparation, time off work
and may give rise to additional health risks.
We recently published a study, based in a North
American population, describing a blood-based, nonin-
vasive risk stratification tool aimed at enhancing compli-
ance and increasing the effectiveness of current CRC
screening regimens. In that study we applied blood
RNA profiling and quantitative real-time RT-PCR to
measure the expression of seven biomarker genes for
CRC. We described a logistic regression algorithm
which calculates a patient’s rank, relative to the average
risk population, in order to predict the patient’s current
risk of having CRC [6].
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sensitivity of 72% and a specificity of 70%, and was not
proposed as a stand-alone test or screening tool. Rather,
the panel provides information that was used to develop
a risk stratification test for CRC that a clinician can use
to triage patients for invasive and scarce technologies
such as colonoscopy. An editorial accompanying the
report describes the work as a “conceptually novel
approach” that is “potentially a substantial step ahead in
cancer screening technologies” [7].
In this report we tested this seven-gene biomarker
panel in a Malaysian population. The Malaysian popula-
tion differs from the North American in two important
respects. First, the Malaysianp o p u l a t i o nc o m p r i s e sd i f -
ferent ethnic groups, each with different susceptibilities
to CRC: Chinese Malaysians have the highest incidence
rates of CRC, with an Age Standardized Rate (ASR) of
21.4 per 100,000; Indian Malaysians have an ASR of
11.3 per 100,000; and ethnic Malays have the lowest
ASR of 9.5 per 100,000 [2]. Furthermore, CRC in Asian
populations are more likely to be flat or depressed (non-
polypoid) cancers or to arise de novo [8]. This presenta-
tion differs from western populations in which most
colorectal cancers arise from precursor adenomatous
polyps, which may take 10-12 years to progress to
malignant cancer [9]. The specific differences in inci-
dence between Asian groups and in the localization and
distinct type of precursor lesions in the Asian popula-
tions suggest genetic variables [8].
Thus in our current study, our objective is to validate
in a genetically and racially diverse Malaysian population
our North American findings that a seven gene biomar-
ker panel can differentiate colorectal cancer from
controls.
Methods
Patient Samples
Blood samples were taken from patients referred to
colonoscopy clinics in Lam Wah Ee Hospital, Penang,
Malaysia, over a two-year period from August 2007 to
November 2009. Patients meeting defined inclusion and
exclusion criteria for the study were enrolled. Patients
provided a blood sample prior to endoscopy, and anon-
ymous clinical data was collected from each subject.
Informed consent was obtained as approved by the insti-
tutions’ Research Ethics Board and Joint Ethics Commit-
tee. All subjects were 21 years or older, and subjects
with known, blood-borne infectious diseases (e.g. HIV,
HCV) were excluded.
Isolation of Whole Blood RNA
All blood specimens were collected prior to colonoscopy
using PAXgene™tubes (PreAnalytix) and processed
according to the PAXgene Blood RNA Kit protocol.
Blood specimens for RNA isolation and downstream
testing were kept refrigerated after collection and during
transportation to GeneNews (Malaysia) Laboratory, a
Standards Malaysia ISO-17025 accredited laboratory at
Mount Miriam Cancer Hospital in Penang. RNA quality
was assessed using Agilent 2100 Bioanalyzer RNA 6000
Nano Kit (Agilent Technologies). RNA quantity was
determined by absorbance at 260 nm in a DU800 Spec-
trophotometer (Beckman-Coulter). The acceptance cri-
teria for the RNA samples are: RIN ≥ 7.0; rRNA ratio ≥
1.0 and a validated Agilent Bioanalyzer scan.
Quantitative Reverse-Transcriptase Polymerase Chain
Reaction
Quantitative reverse-transcriptase real-time RT-PCR
reaction procedures for the seven gene biomarkers
(ANXA3, CLEC4D, TNFAIP6, LMNB1, PRRG4, VNN1
and the duplex partner or reference gene, IL2RB) have
been described previously [6]. Briefly, one microgram of
RNA was reverse-transcribed into single-stranded com-
plementary DNA (cDNA) using the High Capacity cDNA
Reverse Transcription Kit (Applied Biosystems) in 1X RT
reaction. For qPCR, 20 ng cDNA was mixed with Quanti-
Tect® Probe PCR Master Mix (Qiagen) and Taqman®
dual-labeled probe and primers corresponding to the
gene-of-interest and reference gene, IL2RB, in a 25 μL
reaction volume. PCR amplification was performed using
a 7500 Real-Time PCR System (Applied Biosystems).
Up to 4 samples - each sample run in duplicate - can be
analyzed on a single plate. Water was added to the outer
wells to ensure proper temperature equilibrium. No-tem-
plate controls (NTC) containing water and master mix
Table 1 Blood Specimen Collection and RNA Sample
Quality Statistics
Collection Date RNA QC CASES
Control CRC
August 2007 PASS 301 107
To FAIL 8 5
November 2009 Subtotal 309 112
Total 421
Passing Rate 96.9%
Table 2 Gender and Age Distribution in the Study
Samples
Age ≤
30
31 -
50
51 -
70
71 -
90
≥
91
Total Median
Age
Control Male 0 7 37 12 0 56 64
Female 1 14 31 9 0 55 61
CRC Male 0 7 26 18 0 51 66
Female 1 11 22 12 2 48 62
Total Sample
No.
2 39 116 51 2 210
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test contamination. Column 2 and column 11 were desig-
nated for pooled blood RNA (PBR) samples for monitor-
ing the performance of both RT and qPCR steps. PBR was
prepared from blood RNA isolated from specimens col-
lected from volunteers. Wells from row 2 to row 7 were
designated for the corresponding six biomarkers, ANXA3,
CLEC4D, TNFAIP6, LMNB1, PRRG4 and VNN1. IL2RB
served as the reference gene for the six biomarkers.
Results
Over the two-year period 2007 to 2009, we collected
421 blood samples, of which about one quarter were
obtained from CRC patients. More than 95% of the
samples passed quality control criteria (Table 1).
CRC samples were matched to an approximately equal
number of control samples for gender and age, and a
total of 210 samples (99 samples from CRC and 111
from controls) were selected for this investigation. The
age and sex distributions of the samples are shown in
Table 2. The median age for CRC patients and controls
ranged from 61 to 66. More than 80% of the samples
selected were from patients more than 50 years old. The
samples also reflected the multi-ethnic nature of the
Malaysian population, a racial and ethnic mix quite dif-
ferent from the North American samples used in
Table 3 Racial/Ethnic Composition of North American and Malaysian Samples
Patient Race/Ethnicity North American Malaysian
Training Set Test Set
Control CRC Control CRC Control CRC
Number 120 112 208 202 111 99
White 101 (84.2) 91 (81.3) 162 (77.9) 138 (68.3) 1 (0.9)
Black 7 (5.8) 7 (6.2) 8 (3.9) 8 (4.0)
Asian 9 (7.5) 6 (5.4) 32 (15.4) 35 (17.3)
Chinese 74 (66.7) 70 (70.7)
Indian, East 2 (1.8) 3 (3.0)
Indonesian 32 (28.8) 21 (21.2)
Malay 2 (1.8) 5 (5.1)
Others 3 (2.5) 8 (7.1) 6 (2.8) 5 (2.5)
Not Available 16 (7.9)
Note: Percentages within individual cohort are shown in brackets.
Figure 1 Comparison of the Expression of Six Genes of Interest (ANXA2, CLEC4D, LMNB1, PRRG4, TNFAIP6 and VNN1) in CRC (N = 99)
and Controls (N = 101) as shown in Raw Ct-values. (Error bars denote Standard Errors of the Mean) All six biomarkers are shown as up-
regulated genes in CRC as compared with controls.
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quarters of North American samples were from white
patients; about the same percentage of the Malaysian
samples were from Chinese subjects and the remainder
were obtained from East Indians, Indonesians and
Malays.
Quantitative RT-PCR was performed on all the
selected samples, following the protocol established in
Canada [6]. Differential gene expression between CRC
and control groups was estimated using the “compara-
tive cycle threshold (ΔCt) method” of relative quantifica-
tion, which normalizes the Ct values relative to the
reference gene [10]. The expression of the seven-gene
panel in CRC and controls is shown in Figure 1 and Fig-
ure 2. The results are shown as the average Ct for the
six genes of interest (ANXA3, CLEC4D, LMNB1,
PRRG4, TNFAIP6 and VNN1; numbered from 1 to 6)
and their partner or reference gene, IL2RB. The error
bars show the standard errors of the mean, reflecting
the gene expression distributions for the seven biomar-
kers in the CRC and control samples. All six genes of
interest are up-regulated and the reference gene is
down-regulated in CRC as compared with control sam-
ples. These results confirm our finding of differential
gene expression in the seven-gene panel for CRC. The
relative fold-changes (CRC versus controls) for the 6
biomarkers in the Malaysian samples were compared
with the data obtained from North America samples.
The degree and significance of the fold changes are
shown in Table 4. All six biomarkers were significantly
up-regulated in CRC as compared with the control sam-
ples. The data were also evaluated using Mann-Whitney
independent sample rank sum tests, and the results
were highly statistically significant in both the North
American and Malaysian studies (p < 0.0005).
The performance characteristics of the Malaysian sam-
ples were demonstrated by logistic regression multivari-
ate analysis. For the comparison study with the data
obtained in North America, a common classification
table cutoff or threshold value was set (P = 0.5) for the
logistic regression analysis. The performance character-
istics yielded a specificity of 77%, a sensitivity of 61%,
Figure 2 Comparison of the Expression of Partner or Reference Gene (IL2RB) for the corresponding six biomarkers (numbered from 1
to 6) in CRC (N = 99) and Controls (N = 101). The figure shows the reference gene as down-regulated as compared with control samples.
Table 4 Expression of Gene Biomarkers in North American and Malaysian Samples
Symbol Parameter ANXA3 CLEC4D LMNB1 PRRG4 TNFAIP6 VNN1
North Fold Change 1.71 1.50 1.37 1.72 1.58 1.53
American p-Value < 0.0001 < 0.0001 < 0.0001 < 0.0001 < 0.0001 < 0.0001
Malaysian Fold Change 2.06 1.75 1.65 1.37 1.80 1.87
p-Value < 0.0001 < 0.0001 < 0.0001 < 0.0003 < 0.0001 < 0.0001
Note: North American Training Set comprises 112 CRC and 120 control samples.
Malaysian Study Set comprises 99 CRC and 111 control samples.
The significance of the fold changes were evaluated using Mann-Whitney independent sample rank sum tests.
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the Receiver Operating Characteristic (ROC) was 0.76
(95% Confidence Interval: 0.70 to 0.82). These results
are comparable to data obtained from the North Ameri-
can samples and are presented in Table 5.
The gene expression levels are continuous variables,
which makes it possible to define a threshold for opti-
mum sensitivity and specificity that is best suited for the
intended application. As shown in Figure 3, at an opti-
mized threshold (P = 0.4327) for the ROC, 71.7% sensi-
tivity and 71.2% specificity were achieved.
The data were also subjected to 1000 iterations of 2-
fold cross-validation. Figure 4 shows AUC of ROC ana-
lysis with 1000 sets of randomly re-labeled samples
using data from 99 CRC and 111 controls. There is a
distinct separation between the null and true data sets
with only about 2% overlap; this verifies that the seven
CRC biomarkers provide good power to discriminate
between CRC and controls, which is unlikely due to
random chance.
Discussion
Current CRC screening programmes are complex, with
multiple options. Despite efforts to establish mass popu-
lation screening for CRC, screening tests remain proble-
matic and compliance remains suboptimal [11].
Table 5 Comparison on Logistic Regression Analyses
between North American and Malaysian Samples
Study Location North American Malaysian
Training Set Test Set
Sample Size 232 410 210
CRC 112 202 99
Control 120 208 111
Cut-off Value P = 0.5 P = 0.5 P = 0.5
Area under ROC Curve
(95% CI)
0.80
(0.74 - 0.85)
0.80
(0.76 - 0.84)
0.76
(0.70 - 0.82)
Significant Level P < 0.0001 P < 0.0001 P < 0.0001
Sensitivity 82% 72% 61%
Specificity 64% 70% 77%
Accuracy 73% 71% 70%
Note: The MedCalc software, version 11.3 (Broekstraat 52, Mariakerke,
Belgium) was used for the statistical analysis. CI denotes confidence interval.
Figure 3 Area Under the Curve (AUC) of the Receiver Operating Characteristic Curve (ROC) Analysis with 95% Confidence Limits (AUC =
0.76 and CI: 0.70 - 0.82) and at the Optimized Thresholds (P = 0.4327) for Sensitivity and Specificity. Note: The MedCalc software, version
11.3 (Broekstraat 52, Mariakerke, Belgium) was used for the statistical analysis. CI denotes confidence interval.
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inexpensive test with a sensitivity of about 95% and a
specificity about 90%. Fecal Occult Blood Tests (FOBT)
are the most common tests for CRC screening, with
sensitivities of about 64.3% and 81.8%, respectively for
gFOBT (guaiac-based fecal occult blood test) and FIT
(fecal immuno-chemical test) [12]. The effectiveness of
fecal screening, however, requires patient compliance
with testing over many years, and the majority of cases
identified by occult blood testing are false-positives,
which subjects patients to unnecessary further investiga-
tions [1]. Colonoscopy is considered the gold standard
for CRC diagnosis, and is more likely to identify lesions
than any other screening test. However, colonoscopy
requires patient sedation, vigorous bowel preparation
and carries a higher risk of complications than does
other tests.
In light of the difficulties of screening, clinical practice
guidelines for CRC population screening were recently
updated [12], and it was concluded that “ideally, screen-
ing should be supported in a programmatic fashion that
begins with risk stratification and the results from an
initial test and continues through proper follow-up
based on findings.” Our recently introduced blood-based
biomarker panel test for colorectal cancer addresses this
need for risk-stratification. We showed that whole-blood
gene expression profiling can stratify individuals accord-
ing to their current risk of having CRC [6]. The blood-
based seven-gene biomarker panel test benefits patients
who wish to have information about their CRC risk sta-
tus prior to considering current screening procedures.
(Such patients may be uncomfortable with current
screening procedures due to fear of health risks, discom-
fort, cultural, personal or other reasons)
The blood-based test employs receiver operator char-
acteristic (ROC) curve analysis of the expression of six
genes of interest relative to a reference gene. Continu-
ous biomarker outputs are estimated; thus a threshold
can be set to achieve a combination of sensitivity and
specificity that best fits the intended use of the test. By
contrast, current CRC tests such as gFOBT, FIT, fecal
DNA test, are discrete, yielding yes-or-no information.
On the basis of the biomarker test, patients can be
stratified by their current risk of CRC. Our calculations
showed that by using our test it is possible to stratify
the average risk population and select those patients
with an elevated risk for CRC of 2 times or higher, such
that 51% of the cancers can be found by performing
colonoscopy on only 12% of the population. This is
equivalent to a four-fold increase in detection rates, and
can substantially increase healthcare efficiency and the
use of scarce resources such as colonoscopy [6].
Conclusion
In this study, we independently confirm that a seven-
gene biomarker panel validated in a North American
population is also applicable for current CRC risk strati-
fication in a Malaysian population. The extension of the
North American findings lends considerable indepen-
dent validity to the blood-based CRC test, supporting
the clinically utility of the risk stratification approach
across different ethnicities.
Figure 4 Area Under the Curve (AUC) of the Receiver Operating Characteristic (ROC) Analysis Based on 1000X 2-Fold Cross Validation
(99 CRC and 111 Control Samples). This chart displays the distribution for 1000 iterations of 2-Fold cross-validation using 1000 sets of
randomly re-labeled samples generated from 99 CRC and 111 control samples.
Yip et al. Journal of Experimental & Clinical Cancer Research 2010, 29:128
http://www.jeccr.com/content/29/1/128
Page 6 of 7Author details
1Hospital Lam Wah Ee, 141 Jalan Tan Sri Teh Ewe Lim, 11600 Jelutong,
Penang Malaysia.
2GeneNews (M) Sdn Bhd, Mount Miriam Cancer Hospital,
23 Jalan Bulan, 11200 Tanjong Bungah, Penang, Malaysia.
3Research
Department, GeneNews Ltd, 2 East Beaver Creek Road, Building 2, Richmond
Hill, Ontario, L4B 2N3, Canada.
4Department of Hematology, Brigham and
Women’s Hospital, Harvard Medical School, Karp Research Building, Sixth
Floor, 75 Francis Street, Boston, MA, 02115, USA.
Authors’ contributions
DS and CRL drafted the manuscript. GHN carried out the RT-PCR and data
analysis; KTY and PKD examined and diagnosed the patients, collected
patient records, participated in the design of the study and critically
reviewed the manuscript; CCL conceived the study and critically reviewed
the manuscript. All authors have read and approved the final manuscript.
Competing interests
David Suria, Chun Ren Lim, Choong Chin Liew and Guey Hooi Ng are
employees of or consultants to GeneNews Ltd, who sponsored this research.
Received: 26 August 2010 Accepted: 16 September 2010
Published: 16 September 2010
References
1. World Gastroenterology Organization/International Digestive Cancer
Alliance: Practice Guidelines: Colorectal Cancer Screening World
Gastroenterology Organization 2007.
2. National Cancer Registry: Malaysia Cancer Statistics: Data and Figures
Peninsular Malaysia Kuala Lumpur: Ministry of Health Malaysia 2006.
3. US Department of Health and Human Services Centers for Disease Control
and Prevention: Colorectal cancer test use among persons aged greater
than or equal to 50 years – United States, 2001. MMWR 2003, 52:193-196.
4. Zarychanski R, Chen Y, Bernstein CN, Hebert PC: Frequency of colorectal
screening and the impact of family physicians on screening behaviour.
CMAJ 2007, 177:593-597.
5. Sewich MJ, Fournier C, Ciampi A, Dyachanko A: Adherence to colorectal
cancer screening guidelines in Canada. BMC Gastroenterology 2007, 7:39.
6. Marshall KW, Mohr S, El Khettabi F, Nossova N, Chao S, Bao W, Ma J, Li XJ,
Liew CC: Blood-based Biomarker Panel for Stratifying Current Risk for
Colorectal Cancer. Int J Cancer 2010, 126:1177-1186.
7. von Knebel Doeberitz M: Editorial. Int J Cancer 2010, 126:1037-1038.
8. Sung JJY, Lau JYW, Goh KL, Leung WK, for the Asia Pacific Working Group
on Colorectal Cancer: Increasing incidence of colorectal cancer in Asia:
Implications for screening. Lancet Oncology 2005, 6:871-876.
9. Goh KL, Quek KF, Yeo GT, Hilmi IN, Lee CK, Hasnida N, Aznan M, Kwan KL,
Ong KT: Colorectal Cancer in Asians; a demographic and anatomic
survey in Malaysian patients undergoing colonoscopy. Aliment Pharmacol
Ther 2005, 22:859-864.
10. Livak KJ, Schmittgen TD: Analysis of Relative Gene Expression Data Using
Real-Time Quantitative PCR and the 2
-ΔΔC
T Method. Methods 2001,
25:402-408.
11. Smith RA, Cokkinides V, Brooks D, Saslow D, Brawley OW: Cancer Screening
in the United States, 2010: A Review of Current American Cancer
Society Guidelines and Issues in Cancer Screening. CA Cancer J Clin 2010,
60:99-119.
12. Levin B, Lieberman DA, McFarland BM, Smith RA, Brooks D, Andrews KS,
Dash C, Giardiello FM, Glick S, Levin TR, Pickhardt P, Rex DK, Thonrson A,
Winawer SJ: Screening and Surveillance for the Early Detection of
Colorectal Cancer and Adenomatous Polyps, 2008: A Joint Guideline
from the American Cancer Society, the US multi-Society Task Force on
Colorectal Cancer, and the American College of Radiology. CA Cancer J
Clin 2008, 58:130-160.
doi:10.1186/1756-9966-29-128
Cite this article as: Yip et al.: A case-controlled validation study of a
blood-based seven-gene biomarker panel for colorectal cancer in
Malaysia. Journal of Experimental & Clinical Cancer Research 2010 29:128.
Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
Yip et al. Journal of Experimental & Clinical Cancer Research 2010, 29:128
http://www.jeccr.com/content/29/1/128
Page 7 of 7